FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146275200> ?p ?o ?g. }

• W2146275200 endingPage "37" @default.
• W2146275200 startingPage "33" @default.
• W2146275200 abstract "The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin, has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We were interested in determining whether this regimen would be effective and tolerable for Chinese patients.Thirty-two patients with refractory/relapsed non-Hodgkins lymphoma (23 intermediate-grade and nine high-grade) were enrolled in this study. Etoposide was administered at a dose of 40 mg/m2/day as a 1 h intravenous infusion from day 1 to day 4, solumedrol 500 mg/day was given as a 15 min intravenous infusion from day 1 to day 5, ara-C 2 g/m2 was given as a 2 h intravenous infusion on day 5 and cisplatin was given at a dose of 25 mg/m2/day as a continuous infusion from day 1 to day 4. Clinical efficacy and toxicity were assessed on the basis of the WHO criteria.Ten patients (31.3%, 95% Cl 15.2-47.4%) attained complete remission (CR) and seven had partial remission (PR). The overall response rate was 53.1% (95% Cl 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC < 1000/microliter) lasted for an average of 12 days and thrombocytopenia (< 25,000/microliter) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2, 22% grade 3), stomatitis in 72% (25% grade 2, 28% grade 3, 13% grade 4), hepatotoxicity in 9% (3% grade 2), renal toxicity in 13% (6% grade 2, 3% grade 3) and infection in 56% (18% grade 2, 25% grade 3, 13% grade 4). The majority of the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months.ESHAP is an active and tolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival." @default.
• W2146275200 created "2016-06-24" @default.
• W2146275200 creator A5008774660 @default.
• W2146275200 creator A5040640232 @default.
• W2146275200 creator A5049496999 @default.
• W2146275200 creator A5056084189 @default.
• W2146275200 creator A5064426920 @default.
• W2146275200 creator A5070615271 @default.
• W2146275200 creator A5084631637 @default.
• W2146275200 date "1999-01-01" @default.
• W2146275200 modified "2023-10-16" @default.
• W2146275200 title "ESHAP as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma: Taiwan Experience" @default.
• W2146275200 cites W1605164920 @default.
• W2146275200 cites W1862918409 @default.
• W2146275200 cites W1880372716 @default.
• W2146275200 cites W1881397173 @default.
• W2146275200 cites W1933973263 @default.
• W2146275200 cites W197652455 @default.
• W2146275200 cites W2013907298 @default.
• W2146275200 cites W2019731257 @default.
• W2146275200 cites W2117964879 @default.
• W2146275200 cites W2137920066 @default.
• W2146275200 cites W2313423582 @default.
• W2146275200 cites W2343527457 @default.
• W2146275200 cites W3024436806 @default.
• W2146275200 cites W4238900946 @default.
• W2146275200 cites W4293241248 @default.
• W2146275200 doi "https://doi.org/10.1093/jjco/29.1.33" @default.
• W2146275200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10073149" @default.
• W2146275200 hasPublicationYear "1999" @default.
• W2146275200 type Work @default.
• W2146275200 sameAs 2146275200 @default.
• W2146275200 citedByCount "20" @default.
• W2146275200 countsByYear W21462752002014 @default.
• W2146275200 countsByYear W21462752002016 @default.
• W2146275200 countsByYear W21462752002017 @default.
• W2146275200 countsByYear W21462752002018 @default.
• W2146275200 countsByYear W21462752002020 @default.
• W2146275200 countsByYear W21462752002021 @default.
• W2146275200 countsByYear W21462752002022 @default.
• W2146275200 crossrefType "journal-article" @default.
• W2146275200 hasAuthorship W2146275200A5008774660 @default.
• W2146275200 hasAuthorship W2146275200A5040640232 @default.
• W2146275200 hasAuthorship W2146275200A5049496999 @default.
• W2146275200 hasAuthorship W2146275200A5056084189 @default.
• W2146275200 hasAuthorship W2146275200A5064426920 @default.
• W2146275200 hasAuthorship W2146275200A5070615271 @default.
• W2146275200 hasAuthorship W2146275200A5084631637 @default.
• W2146275200 hasBestOaLocation W21462752001 @default.
• W2146275200 hasConcept C121332964 @default.
• W2146275200 hasConcept C126322002 @default.
• W2146275200 hasConcept C141071460 @default.
• W2146275200 hasConcept C142424586 @default.
• W2146275200 hasConcept C2776694085 @default.
• W2146275200 hasConcept C2778041864 @default.
• W2146275200 hasConcept C2778119113 @default.
• W2146275200 hasConcept C2780775027 @default.
• W2146275200 hasConcept C2780873365 @default.
• W2146275200 hasConcept C2781413609 @default.
• W2146275200 hasConcept C29730261 @default.
• W2146275200 hasConcept C71924100 @default.
• W2146275200 hasConcept C87355193 @default.
• W2146275200 hasConcept C90924648 @default.
• W2146275200 hasConceptScore W2146275200C121332964 @default.
• W2146275200 hasConceptScore W2146275200C126322002 @default.
• W2146275200 hasConceptScore W2146275200C141071460 @default.
• W2146275200 hasConceptScore W2146275200C142424586 @default.
• W2146275200 hasConceptScore W2146275200C2776694085 @default.
• W2146275200 hasConceptScore W2146275200C2778041864 @default.
• W2146275200 hasConceptScore W2146275200C2778119113 @default.
• W2146275200 hasConceptScore W2146275200C2780775027 @default.
• W2146275200 hasConceptScore W2146275200C2780873365 @default.
• W2146275200 hasConceptScore W2146275200C2781413609 @default.
• W2146275200 hasConceptScore W2146275200C29730261 @default.
• W2146275200 hasConceptScore W2146275200C71924100 @default.
• W2146275200 hasConceptScore W2146275200C87355193 @default.
• W2146275200 hasConceptScore W2146275200C90924648 @default.
• W2146275200 hasIssue "1" @default.
• W2146275200 hasLocation W21462752001 @default.
• W2146275200 hasLocation W21462752002 @default.
• W2146275200 hasOpenAccess W2146275200 @default.
• W2146275200 hasPrimaryLocation W21462752001 @default.
• W2146275200 hasRelatedWork W1988439337 @default.
• W2146275200 hasRelatedWork W2040492280 @default.
• W2146275200 hasRelatedWork W2146275200 @default.
• W2146275200 hasRelatedWork W2252341082 @default.
• W2146275200 hasRelatedWork W2363793897 @default.
• W2146275200 hasRelatedWork W2399102665 @default.
• W2146275200 hasRelatedWork W2406687475 @default.
• W2146275200 hasRelatedWork W2890971980 @default.
• W2146275200 hasRelatedWork W3031323949 @default.
• W2146275200 hasRelatedWork W3151155646 @default.
• W2146275200 hasVolume "29" @default.
• W2146275200 isParatext "false" @default.
• W2146275200 isRetracted "false" @default.
• W2146275200 magId "2146275200" @default.
• W2146275200 workType "article" @default.